Nanobusiness News

RSS

Restructuring Prepares Company for Product Commercialization

Paragon Intellectual Properties, LLC, today announced that it has restructured the company, moving from a limited liability company with seven subsidiaries to a single C-corporation to form Nexeon MedSystems, Inc. This r...

8 Oct 2008

Researchers Developed a New and Cost-Effective Alternative to Conventional Seals

From petroleum to food and beverage to pharmaceuticals, most industries use mechanical pumps, and all these pumps rely on seals to reduce leaks and maintenance costs. Argonne researchers, along with industry partners, have developed a new, efficient and cost-effective alternative to conventional seals.

8 Oct 2008

MDRNA Advances RNAi Pipeline Toward Human Clinical Development

MDRNA, Inc. announced today that it has advanced its RNAi pipeline with the selection of a Lead Candidate in its hypercholesterolemia program targeting Apolipoprotein B (ApoB). The compound, designated MDR-04227, was dev...

8 Oct 2008

Applied Nanotech Expands Research Agreement

Applied Nanotech Holdings, Inc. today announced that the third phase of its research project with a leading industrial chemical products company in Japan, announced on September 29, 2008, has been expanded and the previo...

From Nano Magic, LLC. 8 Oct 2008

Particle Sciences Sells Proprietary Line of Microfine Titanium Dioxide to Sensient

Particle Sciences announced today that it has sold T-COTE, its proprietary line of microfine titanium dioxide, to Sensient. With the sale, Sensient assumes all marketing and sales responsibilities and acquires the associ...

8 Oct 2008

NCCN Announces Collaboration to Conduct Anti-Cancer Drug Studies

The National Comprehensive Cancer Network (NCCN), Abraxis BioScienc, and AstraZeneca today announced that they have entered into a collaboration to conduct multiple investigator-initiated studies of Abraxis BioScience's anti-cancer drug ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound), which is based on the company's proprietary tumor targeting technology known as the nab(TM) platform.

8 Oct 2008

Nanobusiness News

Restructuring Prepares Company for Product Commercialization

Researchers Developed a New and Cost-Effective Alternative to Conventional Seals

MDRNA Advances RNAi Pipeline Toward Human Clinical Development

Applied Nanotech Expands Research Agreement

Particle Sciences Sells Proprietary Line of Microfine Titanium Dioxide to Sensient

NCCN Announces Collaboration to Conduct Anti-Cancer Drug Studies

Company Achieves Substantial Cost Savings With PLM Investment

WaferGen Signs Distribution Agreements for SmartSlide Micro-Incubation System in Europe and Asia

First and Only Anti-Cancer siRNA Drug Candidate Currently Undergoing Human Clinical Trials

The Foundry Company to Build New State-of-the-Art Manufacturing Facility

Revolutionary Nanofibers Made from Flour for Tissue Regeneration

A New Language for Nanopore Design

Enhancing Solid-State Lithium Batteries with Nano-Ceramic Electrolytes

Automated Image Acquisition and Analysis of Graphene and Hexagonal Boron Nitride Structures

A Novel Approach to Enhancing Lithium-Ion Battery Performance with Graphene

Conversations on AFM: Applications of BioAFM in Life Science

Conversations on AFM: The Technology and History Behind AFM and SPM

Recent Advances in High-Speed Atomic Force Microscopy to Improve Research Into Protein Dynamics

Sponsored Content

The Evolution of Lipid Nanoparticles

How Emulsion Electrospinning is Transforming Materials

What are Mesoporous Silica Nanoparticles?

Carbon-Based Nanomaterials: Overcoming Challenges in Air Sensitivity for Next-Generation Batteries